SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

ConditionNon-hodgkin Lymphoma,B Cell

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorFondazione Italiana Linfomi - ETS

About this trial

This is a multicenter prospective observational study lead by the FIL on sarcopenia and sGA as possible predictors of efficacy and toxicity outcomes in patients undergoing CAR-T cells treatment.

Eligibility criteria

Qualifiers

Adult patients (≥ 18 years old).

Patients with B-cell non-Hodgkin Lymphoma scheduled to received CAR-T cell product according to Agenzia Italiana del Farmaco (AIFA) indications and technical data sheet of the drug

Availability of a 18F-FDG PET/CT scan or a full dose CT scan (without contrast media) pre-treatment with CART

Written informed consent voluntarily provided

Disqualifiers

Patients not fulfilling the eligibility criteria

Trial design

Treatments tested in this trial

Chimeric Antigen Receptor T-cells (CAR-T) therapy

Treatment groups

130 Participants

are divided into 1 treatment group

Locations

A.O. SS. Antonio e Biagio e Cesare Arrigo - S.C.D.U. Ematologia Alessandria Italy

AOU Ospedali Riuniti - Clinica di Ematologia Ancona Italy

Azienda Ospedaliera S .Giuseppe Moscati - S.C. Ematologia e Trapianto emopoietico Avellino Italy

IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati Aviano Italy

Sponsors and collaborators

Fondazione Italiana Linfomi - ETS

Lead sponsor

Kite, A Gilead Company

Collaborator

Source ClinicalTrials.gov